Drug-resistant infections could claim millions more lives and severely damage the global economy by 2050, according to new modelling. The study, funded by the UK government and conducted by the Center for Global Development, warns that antimicrobial resistance (AMR) could reduce global GDP by $1.7 trillion annually if no action is taken.
Major economies such as the US, UK, and EU are projected to suffer the greatest economic hits, sparking criticism over recent cuts to foreign aid budgets. The UK, for instance, recently ended support for the Fleming Fund, which helps combat AMR in developing nations. Similar aid reductions have been confirmed by the US and several European countries.
Deaths from AMR are expected to rise by 60% by 2050, with an estimated 1.34 million deaths per year in the US and 184,000 in the UK. Resistant infections also place a greater strain on health systems, doubling treatment costs due to longer hospital stays and more intensive care. The study also found that AMR would reduce the UK workforce by a staggering 0.8% if higher rates of antibiotic-resistant infections persist.
Treating AMR could push global health spending up by $176 billion annually. However, the study highlights that stronger investment in prevention and new treatments could boost economic output, with the US gaining $156 billion a year and the UK $12 billion by 2050.
Responding to the news, a UK government spokesperson stated that the recently announced NHS 10-Year Plan recognises AMR’s threat and has committed to curbing its rise, while they remain focused on building upon progress and working with international partners to tackle the problem.
